Researchers Seek Pleural Effusions And Tissue to Create MCB Cell Lines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

BOSTON, Mass--Under a grant from the US Army Breast Cancer Program, Harvard researchers are attempting to create medullary carcinoma of the breast (MCB) cell lines as part of their immunologic studies. There is currently only one line in the world for this infrequent tumor. "We are especially interested in pleural effusions (or ascites)--the best source to make cell lines--but will also use fresh, unfixed tumor tissue, and will pay all shipping costs," said investigator Richard Junghans, PhD, MD.

BOSTON, Mass--Under a grant from the US Army Breast Cancer Program,Harvard researchers are attempting to create medullary carcinomaof the breast (MCB) cell lines as part of their immunologic studies.There is currently only one line in the world for this infrequenttumor. "We are especially interested in pleural effusions(or ascites)--the best source to make cell lines--but will alsouse fresh, unfixed tumor tissue, and will pay all shipping costs,"said investigator Richard Junghans, PhD, MD.

Departments are asked to post the request, which remains in effectuntil January 1, 1998. Prior to thoracentesis, or, when possible,tumor excision, please call Dr. Junghans or Dr. P. Telleman at617-632-0943; fax: 617-632-0998. (The MCB cell line is from theArmed Forces Institute of Pathology, Atlas #67-1-42.)

Recent Videos
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content